Navigation Links
Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
Date:6/23/2008

Trial design and implementation pioneers from Cytel join peers in examining

the rise of adaptive study approaches and overcoming the remaining

challenges to wider adoption

CAMBRIDGE, Mass., June 23 /PRNewswire/ -- Cytel's renowned adaptive trial design and implementation experts Cyrus Mehta (http://www.cytel.com) and Judith Quinlan (http://www.cytel.com) will lead workshops and case study reviews at the Annual Meeting of the Drug Information Association (DIA) June 22 - 25, 2008 in Boston.

Adaptive trials are finding ever-increasing acceptance by sponsors and regulators seeking to improve clinical development productivity and reduce the rate of trial failures. Combining a wealth of experience designing and implementing adaptive trials together with over 20 years developing software for trial design, simulation and analysis, Cytel's clinical innovation know- how is unmatched.

At this year's DIA meeting, senior managers, clinicians, statisticians and trial logistics professionals from the biopharmaceutical industry will share their recent experiences with adaptive trials, and the insights gained on planning and conducting the next generation of adaptive studies.

Speaking on the latest innovative trial techniques and tools will be Cytel Co-Founder and President, Dr. Cyrus Mehta, and Vice President of Adaptive Trials, Judith Quinlan.

Dr. Mehta will join Dr. William Byrom, Vice President, Product Strategy at trial technology leader ClinPhone, for the workshop "Adaptive Design in Clinical Research", June 23, 10:30A - 12:30P.

Reporting on the PhRMA Working Group for Adaptive Trials efforts to chronicle trial innovation successes, Cytel's Judith Quinlan presents "Are You Ready for Adaptive Clinical Development? Examples, Case Studies, Successes" on June 24, 8:30A - 9:30A.
See the complete DIA meeting website

http://www.diahome.org/DIAHome/FlagshipMeetings/home.aspx?meetingid=14235

and the DIA's blog site

http://www.diaannual.com/

Dr. Mehta and Vice President Quinlan are available for interviews following the DIA conference.


'/>"/>
SOURCE Cytel, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):